代表文章：
（1）Zhiwei Zhang, Caifeng Sun, Lu Zhang, Xinming Chi, Jiamei Ji, Xingjie Gao, Ying Wang, Zinan Zhao, Likun Liu, Xuejiao Cao, Yanqin Yang*（Co-respondence）, Weifeng Mao*, Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin. Biomedicine & Pharmacotherapy 109: 1541–1546, 2019. （2）Yang Y, Yang Z, Han A, Feng R, Ma Y, Kong L, Sun X, Zheng J, Yu J*. Prediction of the outcome of definitive chemoradiation by decrease in F-18 FDG uptake in nonsurgical esophageal squamous cell cancer. Clin Nucl Med, 36(10): 860-6, 2011. （3）Yang Y, Xuan J, Yang Z, Han A, Xing L, Yue J, Hu M, Yu J*. The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapy, Med Oncol, 29(3): 1448-1455, 2012. （4）Yanqin Yang, Jinming Yu*, Ligang Xing, Xingdong Sun, Dianbin Mu, Anqin Han. HIF-1α and EGFR as progonostic factors for therapy response and 1-year locoregional recurrence not for distant metastasis and 2-year OS in unresectable stage IIIA NSCLC treated with combined chemoradiotherapy. Journal of Clinical Oncology. 28:15s (Suppl; abstr 10640), 2010. （5）Yue J, Yang Y, Cabrera AR, Sun X, Zhao S, Xie P, Zheng J, Ma L, Fu Z, Yu J*. Measuring tumor hypoxia with (18) F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study, Dis Esophagus, 25(1):54-61, 2012.
展开